

## Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Review

Wendy van Dorp, Riccardo Haupt, Richard A. Anderson, Renee L. Mulder, Marry M. van den Heuvel-Eibrink, Eline van Dulmen-den Broeder, H. Irene Su, Jeanette F. Winther, Melissa M. Hudson, Jennifer M. Levine, and W. Hamish Wallace

Author affiliations and support information (if applicable) appear at the end of this article.

Published at [jco.org](http://jco.org) on June 6, 2018.

J.M.L. and W.H.W. contributed equally to this work.

Corresponding author: Wendy van Dorp, MD, PhD, Department of Gynaecology and Obstetrics, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; e-mail: [w.vandorp@erasmusmc.nl](mailto:w.vandorp@erasmusmc.nl).

© 2018 by American Society of Clinical Oncology

0732-183X/18/3621w-2169w/\$20.00

### ABSTRACT

Some survivors of childhood, adolescent, and young adult cancer are at increased risk of gonadal dysfunction and adverse pregnancy outcomes. We reviewed currently available literature that evaluated reproductive function and pregnancy outcomes of female cancer survivors diagnosed before the age of 25 years. High-dose alkylating agent chemotherapy and abdominal/pelvic radiotherapy adversely affect gonadal function in a dose-related fashion, with older age at exposure conferring greater risk as a result of the age-related decline in ovarian reserve. Gonadal injury clinically manifests as ovarian hormone insufficiency (delayed or arrested puberty, premature ovarian insufficiency, or premature menopause) and infertility. The effect of molecular-targeted agents on ovarian function has not been established. For female cancer survivors who maintain fertility, overall pregnancy (relative risk, 0.67 to 0.81) and live birth rates (hazard ratio, 0.79 to 0.82) are lower than those in the general public. Pregnancy in cancer survivors also may be associated with risks to both the mother and the fetus related to miscarriage; preterm birth; and, rarely, cardiomyopathy. Women at risk for these complications require preconception assessment and counseling from both obstetricians and oncology providers. The risk for inherited genetic disease in offspring conceived after cancer treatment exposure is not increased. The optimization of reproductive outcomes and minimization of risks of pregnancy complications in survivors requires informed, risk-based assessment and monitoring.

*J Clin Oncol* 36:2169-2180. © 2018 by American Society of Clinical Oncology

### INTRODUCTION

The childhood cancer survivor population has been growing rapidly over the past four decades, with 5-year survival rates now approximately 80% in the developed world. Despite increasing survival, the majority of these survivors will experience at least one and often several chronic health conditions by age 40 years that will significantly affect their overall quality of life.<sup>1,2</sup> Among the health consequences of cancer, gonadal dysfunction and infertility are major concerns of survivors and their parents, which results in distress, fear, anxiety, and interference with intimate relationships.<sup>3</sup> The identification of risk factors that affect reproductive function and fertility is important to facilitate accurate counseling and timely referral for established (eg, oocyte, embryo cryopreservation) and experimental (eg, ovarian tissue cryopreservation) interventions that may help to restore future fertility in high-risk populations.<sup>4</sup> In this review, we assess

currently available literature on reproductive function and pregnancy outcomes of female childhood, adolescent, and young adult cancer survivors diagnosed before the age of 25 years.

### CANCER THERAPY AND GONADAL FUNCTION

Some cancer survivors are at increased risk of damage to reproductive function, which may manifest as ovarian hormone insufficiency (absent or arrested puberty, premature ovarian insufficiency [POI; also referred to as early menopause]), and infertility.<sup>4</sup> POI is a clinical condition that develops in any adult female at an age younger than 40 years and is characterized by the absence of menstrual cycles for  $\geq 4$  months and two elevated serum follicle-stimulating hormone levels in the menopausal range.<sup>5</sup> Compared with siblings, the risk of nonsurgical POI is increased, with a cumulative incidence of approximately 8% to 10% by age 40 years.<sup>6-8</sup> These manifestations generally reflect direct or indirect

adverse effects of cancer treatment on the nonrenewable pool of primordial follicles within the ovary.<sup>9</sup>

The body of evidence that describes adverse effects of multimodal cancer therapies on female reproductive function largely is based on retrospective cohort studies.<sup>10</sup> A dissection of the contribution of individual therapeutic components in these studies often is difficult, but increasingly data have elucidated predisposing treatments. These studies confirm that among chemotherapeutic agents, the alkylating agents impart a higher risk in a dose-related manner when both individual agents and a combination of alkylating agents are used.<sup>11</sup> Of note, no consistent threshold seems to exist for a safe alkylating agent dose.

The ovaries also may be damaged by radiation to a field that potentially exposes them (eg, total body, abdominal, pelvic, spinal irradiation). The magnitude of the effect is related to dose, fractionation schedule, and age at the time of treatment. The oocyte is extremely sensitive to radiation, with < 2 Gy representing the estimated dose required to destroy 50% of primordial follicles<sup>12</sup>; nomograms that identify the dose likely to cause POI across a range of ages have been produced.<sup>4</sup>

Molecular-targeted agents, such as monoclonal antibodies and kinase inhibitors, increasingly have been used in the treatment of female cancer. At present, the effects of such agents on female reproductive function are largely unknown, but reports have proposed a likely transient effect of bevacizumab (an anti-vascular endothelial growth factor agent) on ovarian function.<sup>13</sup> Because follicle growth depends on angiogenesis, normal folliculogenesis may be impaired by this agent; effects on the nongrowing ovarian follicle pool remain unknown. Other agents may have effects on the nongrowing primordial follicle pool through activity on pathways of physiologic relevance to the control of follicle dormancy and growth activation. One potential example of this is imatinib, which has adverse effects on ovarian function<sup>14</sup> but also may have protective effects against the gonadotoxicity of cisplatin.<sup>15</sup> The effect of <sup>131</sup>I-metaiodobenzylguanidine for neuroblastoma is unclear because only two cases have been reported to result in damage to the female gonads, but because of the localization of the tumors (pelvis), the ovaries might have received some scattered irradiation.<sup>16</sup>

## DIAGNOSIS OF POI

In addition to compromising fertility, POI is associated with osteoporosis, cardiovascular disease, impaired well-being, and compromised sexual health.<sup>5,17</sup> Therefore, surveillance of at-risk survivors may facilitate early detection and access to interventions that preserve health and improve quality of life.<sup>18,19</sup>

Several initiatives have developed national guidelines for POI surveillance in survivors.<sup>20-23</sup> However, many differences were observed, which result in difficulties in implementing guidelines in clinical practice. As part of a larger international effort to harmonize existing late-effects screening recommendations for survivors of childhood cancer, POI surveillance recommendations for female survivors were reviewed<sup>19</sup> (Fig 1). Gaps in knowledge also were identified, including the lack of information on safe treatment dosages and the role of genetic susceptibility on subsequent POI risk, to lead future directions in research.

Assessment for POI should begin, as appropriate for age, with documentation of pubertal, menstrual, and pregnancy history and symptoms (eg, hot flashes) and physical findings of

ovarian hormone insufficiency (eg, delayed/stalled puberty). Among useful biomarkers, follicle-stimulating hormone remains the key hormone of diagnostic value for POI, but now, increasing data show the value of anti-Müllerian hormone (AMH) in identifying women with low ovarian reserve after cancer therapy.<sup>24</sup> The value of AMH in predicting early menopause remains uncertain, and a very low AMH does not preclude natural conception. Thus, although this biomarker is of great value in a research context, its value in routine clinical practice is less clear. Antral follicle count by transvaginal ultrasound also is an established method for assessing ovarian reserve in adult women, but it is not part of the definition of POI.

## TREATMENT OF OVARIAN HORMONE INSUFFICIENCY

Sex steroid replacement therapy (SSRT) can remediate or prevent the consequences of estrogen deprivation in survivors with POI. SSRT differs for survivors who are prepubertal and those who experience POI after secondary sexual characteristics have developed. Timing and tempo of estrogen substitution in the prepubertal patient are crucial to ensure normal pubertal development (especially breast development) and an acceptable final height and ideally should be managed by a provider with expertise in pediatric pubertal development. In postpubertal females, SSRT promotes bone and cardiovascular health.<sup>25</sup> Progesterone therapy also is needed to avoid endometrial hyperplasia and cancer in women with a uterus once breast development is complete.

In noncancer survivors, POI is treated with SSRT to remediate symptoms of low estrogen. Moreover, women should be advised that SSRT may play a role in primary prevention of cardiovascular disease and in bone protection.<sup>5</sup> In these women, SSRT use before the age of natural menopause has not been found to increase the risk of breast cancer.<sup>5</sup> Literature on the effects of SSRT in female cancer survivors, however, is scarce. Similarly, limited data exist on oral versus transdermal SSRT administration. A crossover study of oral versus transdermal SSRT in young women with POI related to Turner syndrome and childhood cancer treatment showed that transdermal treatment is more effective than standard oral treatment in terms of bone and cardiovascular health.<sup>26-28</sup> Participant numbers were limited and the study groups heterogeneous, which emphasizes the importance of pursuing randomized studies on SSRT in survivors.

Although most providers uniformly would recommend SSRT to support pubertal development and growth, use of SSRT in older patients is variable partly because of concerns about induction of second malignant neoplasms, especially breast cancer. In this regard, recent research from the Childhood Cancer Survivor Study reported that survivors with POI treated with SSRT have a lower risk of breast cancer than those who continue to menstruate naturally. These data suggest that SSRT does not affect breast cancer risk to the same degree as endogenous hormones.<sup>29</sup>

## PREGNANCY RATES

For survivors of reproductive age, concerns about achieving pregnancy, maternal health during pregnancy, and pregnancy

<b>General recommendation</b>
Survivors treated with one or more potentially gonadotoxic treatments*, and their providers, should be aware of the risk of premature ovarian insufficiency and its implications for future fertility (level A and level C evidence).
<b>Who needs surveillance?</b>
Counselling regarding the risk of premature ovarian insufficiency and its implications for future fertility <i>is recommended</i> for survivors treated with: <ul style="list-style-type: none"> <li>• Alkylating agents in general (level A evidence)</li> <li>• Cyclophosphamide and procarbazine (level C evidence)</li> <li>• Radiotherapy potentially exposing the ovaries (level A evidence)</li> </ul>
<b>What surveillance modality should be used for pre- and peri-pubertal survivors?</b>
Monitoring of growth (height) and pubertal development and progression (Tanner stage) <i>is recommended</i> for pre-pubertal survivors treated with potentially gonadotoxic chemotherapy and/or radiotherapy potentially exposing the ovaries (expert opinion/no literature search). <sup>††</sup>
FSH and oestradiol <i>are recommended</i> for evaluation of premature ovarian insufficiency in pre-pubertal survivors treated with potentially gonadotoxic chemotherapy and/or radiotherapy potentially exposing the ovaries* who fail to initiate or progress through puberty (expert opinion/no literature search). <sup>‡§</sup>
<b>What surveillance modality should be used for post-pubertal survivors?</b>
A detailed history and physical examination with specific attention for premature ovarian insufficiency symptoms, e.g. amenorrhoea and irregular cycles <i>is recommended</i> for post-pubertal survivors treated with potentially gonadotoxic chemotherapy and/or radiotherapy potentially exposing the ovaries (expert opinion/no literature search).*
FSH and oestradiol <i>are recommended</i> for evaluation of premature ovarian insufficiency in post-pubertal survivors treated with potentially gonadotoxic chemotherapy and/or radiotherapy potentially exposing the ovaries* who present with menstrual cycle dysfunction suggesting premature ovarian insufficiency or who desire assessment about potential for future fertility. Hormone replacement therapy should be discontinued prior to laboratory evaluation when applicable (expert opinion/no studies). <sup>§  </sup>
AMH <i>is not recommended</i> as the <i>primary surveillance modality</i> for evaluation of premature ovarian insufficiency in survivors treated with potentially gonadotoxic chemotherapy and/or radiotherapy potentially exposing the ovaries* who desire assessment about potential future fertility (expert opinion/no studies).
AMH <i>may be reasonable</i> in conjunction with FSH and estradiol for identification of premature ovarian insufficiency in survivors treated with potentially gonadotoxic chemotherapy and/or radiotherapy potentially exposing the ovaries* aged ≥25 years who present with menstrual cycle dysfunction suggesting premature ovarian insufficiency or who desire assessment about potential for future fertility (expert opinion/no studies).
<b>When should pre- and peri-pubertal survivors be referred?</b>
Referral to paediatric endocrinology / gynaecology <i>is recommended</i> for any survivor who has <ul style="list-style-type: none"> <li>• No signs of puberty by 13 years of age.</li> <li>• Primary amenorrhoea by 16 years of age.</li> <li>• Failure of pubertal progression.<sup>¶</sup></li> </ul> (expert opinion/no literature search)
<b>When should post-pubertal survivors be referred?</b>
Referral to gynaecology / reproductive medicine / endocrinology (according to local referral pathways) <i>is recommended</i> for post-pubertal survivors treated with potentially gonadotoxic chemotherapy and/or radiotherapy potentially exposing the ovaries* who present with menstrual cycle dysfunction suggesting premature ovarian insufficiency (expert opinion/no literature search).
<b>What should be done when abnormalities are identified in pre-, peri- and post-pubertal survivors?</b>
Consideration of sex steroid replacement therapy <i>is recommended</i> for pre-, peri- and post-pubertal survivors diagnosed with premature ovarian insufficiency <i>by referral to gynaecology/endocrinology</i> (expert opinion/no literature search).
<b>What should be done when potential for future fertility is questioned?</b>
Referral to gynaecology / reproductive medicine / endocrinology (according to local referral pathways) <i>is recommended</i> for post-pubertal females treated with potentially gonadotoxic chemotherapy and/or ovarian irradiation* without signs and symptoms of premature ovarian insufficiency who desire assessment about potential for future fertility (expert opinion/no literature search).

**Fig 1.** Harmonized recommendations for premature ovarian insufficiency (POI) surveillance in survivors of childhood, adolescent, and young adult cancer. POI is a clinical condition that develops in any adult female before age 40 years that is characterized by the absence of menses for > 4 months and two elevated serum follicle-stimulating hormone (FSH) levels in the menopausal range (on the basis of the maximum threshold of the laboratory assay used). (\*) Treatments with evidence of causing POI include alkylating agents in general (level A evidence), cyclophosphamide, procarbazine (level C evidence), and radiotherapy to a field that includes the ovaries (level A evidence). (†) At least annually, with increasing frequency as clinically indicated on the basis of growth and pubertal progression. (‡) At least for girls of ≥ 11 years of age and for girls with primary amenorrhoea (age 16 years). (§) If amenorrhoea, measured FSH and estradiol randomly; if oligomenorrhoea, measured during early follicular phase (days 2 to 5). (||) This assessment should be performed after ending oral contraceptive pill/sex steroid replacement therapy use, ideally after 2 months without oral contraceptive pills. (¶) The absence of initiation of puberty (Tanner stage 2 breast development) in girls ≥ 13 years of age or failure to progress in pubertal stage for ≥ 12 months. AMH, anti-Müllerian hormone; level A, high level of evidence; level B, moderate/low level of evidence; level C, very low level of evidence. Reprinted with permission.<sup>19</sup>

outcomes represent priority health concerns. Large cohort studies have demonstrated that overall, female cancer survivors have lower rates of pregnancy<sup>30-32</sup> and live births<sup>32-35</sup> than their siblings and general population controls (Table 1). Risks for lowest rates occur after exposure to cranial and abdominal radiation. Abdominal radiotherapy also is associated with delayed time to pregnancy,<sup>36</sup> and in a large German cohort of survivors of Hodgkin lymphoma, pelvic radiotherapy was the key determinant of not achieving parenthood.<sup>37</sup> Pelvic radiotherapy also may affect the uterus, with consequences for early and late pregnancy loss and pregnancy complications (see Pregnancy Outcomes).

Chow et al<sup>32</sup> demonstrated that survivors who received chemotherapy alone had lower live birth rates (hazard ratio, 0.82; 95% CI, 0.76 to 0.89). Cyclophosphamide equivalent dose was associated at the highest doses with lower live birth rates (upper quartile v no exposure: hazard ratio, 0.85; 95% CI, 0.74 to 0.98). Detailed information on treatment revealed that only busulfan and lomustine are specific agents associated with a reduced chance of pregnancy. This study also highlighted the effect of delaying pregnancy such that the effect of chemotherapy was magnified in women whose first pregnancy was after 30 years of age; thus, there seems to be some evidence of age-related loss of fertility. These findings have clear implications for advising young women about the timing of pregnancy after cancer treatment. Higher pregnancy rates have been reported in more-recent treatment eras, which likely reflects the risk-adapted use of gonadotoxic treatment modalities.<sup>35</sup>

Pregnancy rates are not synonymous with either fertility or infertility. In the former, factors other than treatment exposure can affect pregnancy, such as having a partner and the desire for having

children. In addition, the presence of clinical infertility does not necessarily preclude pregnancy, especially with the use of assisted reproduction.<sup>36</sup>

## PREGNANCY OUTCOMES


As in the general population, live birth rates in cancer survivors are lower than pregnancy rates, which reflects losses during pregnancy.<sup>32</sup> Cohort and national registry data show that spontaneous pregnancy loss at < 22 weeks of gestation occurs with limited frequency (7% to 15%) in survivors, which is a comparable rate to siblings and population controls.<sup>38-40</sup> However, higher spontaneous pregnancy loss rates have been reported in women exposed to cranial radiation (1.4- to 6.1-fold increase) and abdominopelvic radiation (1.4- to 2.8-fold increase).<sup>33,38,39</sup> Of particular concern is the observation that second trimester losses are significantly increased in women with these exposures.<sup>33,39</sup> Abdominopelvic radiation is hypothesized to damage the endometrium, myometrium, or uterine vessels.<sup>41-43</sup>

Preterm birth at < 37 weeks gestation poses significant risks to offspring and occurs in 13% to 21% of pregnancies in cancer survivors.<sup>44,45</sup> Compared with siblings or the general population, these rates are 1.5- to twofold higher in survivors, including similarly elevated relative risks for early preterm births before 32 weeks.<sup>44-47</sup> Preterm birth risk is related to abdominopelvic radiation in a dose-dependent fashion but does not seem to vary by radiation before or after menarche.<sup>33,39,44</sup> Most reported data have shown no association between preterm birth and exposure to alkylating chemotherapy.<sup>33,44</sup> A dearth of data exists on risks of

**Table 1.** Pregnancy and Live Birth Rates in Childhood Cancer Survivors

First Author	Study Cohort (no. of patients)	Treatment Period	Age at Diagnosis, Years	Control Group	Pregnancy Rates (95% CI)	Live Birth Rates (95% CI)	Risk Estimate
Green <sup>30</sup>	CCSS (5,149)	1970-1986	0-21	Sibling controls	RR, 0.81 (0.73-0.90)	Not reported	Patients with hypothalamic/pituitary radiation dose $\geq$ 30 Gy (RR, 0.61; 95% CI, 0.44 to 0.83) or an ovarian/uterine radiation dose > 5 Gy were less likely to have ever been pregnant
Reulen <sup>33</sup>	BCCSS (10,483)	1940-1991	0-14	General population England and Wales	Not reported	O/E, 0.64 (0.62-0.66)	Brain and abdominal RT
Stensheim <sup>31</sup>	Cancer Registry of Norway (16,105)	1967-2004	16-25 (subset of total study)	General population	HR, 0.67 (0.63-0.73)	Not reported	Not applicable because risks reported for total cohort (age 16-45 years)
Pivetta <sup>34</sup>	Italian AIEOP Off-Therapy Registry (2,670)	1960-1998	0-14	General Population	Not reported	O/E, 0.57 (95th, 0.53-0.62)	Malignancy of the CNS
Chow <sup>32</sup>	CCSS: chemotherapy only (5,298)	1970-1986	0-21	Siblings	HR, 0.87 (0.81-0.94; $P < .001$ )	HR, 0.82 (0.76-0.89; $P < .001$ )	Busulfan and higher doses of lomustine ( $\geq$ 411 mg/m <sup>2</sup> ) and cyclophosphamide equivalent doses in the upper quartile ( $\geq$ 11,295 mg/m <sup>2</sup> ).
Armuaud <sup>35</sup>	Swedish National Patient Register (552)	Born between 1973 and 1977	0-21	Age-matched controls from the general population	Not reported	HR, 0.79 Before 1988 HR, 0.71 After 1988 HR, 0.90	Malignancy of the eye or CNS or leukemia

Abbreviations: AIEOP, Italian Pediatric Ematology and Oncology Association; BCCSS, British Childhood Cancer Survivor Study; CCSS, Childhood Cancer Survivor Study; HR, hazard ratio; O/E, observed/expected; RR, relative risk; RT, radiotherapy.



**Fig 2.** Assessment of the postpubertal survivor. AFC, antral follicle count; AMH, anti-Müllerian hormone; POI, premature ovarian insufficiency.

very early preterm birth (< 28 weeks) as well as on causes of preterm birth (ie, spontaneous *v* iatrogenic). Hence, a lack of studies remains on how to prevent this adverse late effect.

Concordant with higher rates of preterm birth, low-birth-weight babies (< 2,500 g) occur in 7% to 15% of offspring of cancer survivors, which is two- to threefold more frequent than in the offspring of controls.<sup>39,44,45,48</sup> With the exception of abdominopelvic radiation, higher rates of offspring being small for gestational age are not observed, which suggests that most of the low-birth-weight risk is attributable to preterm birth rather than to intrauterine growth restriction.<sup>44,45,49</sup> Overall, cancer survivors do not seem to be at a higher risk for stillbirth versus the general population.<sup>38,47</sup> However, similar to other pregnancy outcomes, abdominopelvic radiation exposure may be associated with a higher risk of perinatal death, but studies are limited in power because of overall low incidence.<sup>33,50-52</sup>

Cancer treatment exposures, including anthracyclines, chest radiation, and molecular-targeted agents, pose cardiovascular risks that can affect pregnancy outcomes. Several cohort studies reported an approximately 5% absolute risk of preeclampsia during pregnancy in cancer survivors, but rates are not higher or only modestly (1.4-fold) higher than in controls.<sup>45,53,54</sup> In the British Childhood Cancer Survivor Study, survivors of Wilms tumor treated with abdominal radiotherapy were at a threefold risk for the

development of hypertension during pregnancy. Pregnancy-associated cardiomyopathy occurred rarely (0.3%) in a retrospective cohort study of 847 survivors, but increased risk was observed with anthracycline exposure.<sup>55</sup> Hence, the International Late Effects of Childhood Cancer Guideline Harmonization Group has recommended that cardiomyopathy surveillance is reasonable before pregnancy or in the first trimester for all female survivors treated with anthracyclines or chest radiation.<sup>56</sup> With the increased use of targeted therapy, long-term and pregnancy-related cardiotoxicity of these agents requires additional study.

During pregnancy, overall rates of gestational diabetes are low (< 5%) and not consistently higher in cancer survivors than in controls.<sup>45,54</sup> However, abdominal radiation has been associated with a 2.7- to 4.7-fold higher risk in one study.<sup>53</sup> Cesarean deliveries are consistently 1.2- to 2.3-fold higher in survivors than in controls.<sup>45,54</sup>

Because of these potential pregnancy-related complications, survivors would benefit from preconception counseling to estimate the magnitude of risk, establish a surveillance plan, and discuss interventions to reduce risk; obstetricians and oncology providers must be aware of these complications to manage survivors accordingly (Fig 2). A dearth of intervention studies has focused on improving these adverse perinatal outcomes. Moreover, these data were derived from cohorts treated with regimens

**Table 2.** Health Risk Outcomes in Cancer Survivor Offspring

First Author	Study Cohort	No. of Offspring	Outcome Assessment	Comparison	Cancer (treatment)	Health Risk Outcomes Measures	Risk Estimate
Chiarelli <sup>51</sup>	Female CCS: Ontario Cancer Registry, diagnosis < 20 years of age (1964-1988)	594 singleton pregnancies born to 340 CS	Questionnaire	Internal comparison: patients treated with nonsterilizing surgery only or no treatment	Medical records Five treatment groups: AA, AP irradiation (low [ $\leq$ 25 Gy], high [ $>$ 25 Gy]), AA + AP irradiation, and all other treatments	Congenital malformations (n = 22)	CS with AP irradiation (OR, 0.45; 95% CI, 0.12 to 1.70) General: decreased risk of having an infant with a congenital anomaly compared with those having surgery only No effect of high- v low-dose AP radiation (small number)
Winther <sup>58</sup>	CCS: Danish Cancer Registry, diagnosis < 20 years of age (1943-1996)	2,130 born to 550 female and 550 male CS	Registry linkage	General Danish population Internal comparisons	Registry-based information on RT (yes/no) Five categories of estimated radiation dose to gonads: low, low-medium, medium, and high	Sex ratio alterations (2,130 offspring)	Male (0.99):female (1.00) ratio v Danish population (1.06) No effect of RT on the male:female ratio P for trend with ovarian dose = .51
Winther <sup>61</sup>	CCS: Danish Cancer Registry, diagnosis < 20 years of age (1943-1996)	2,630 born to 4,676 female and male CS	Registry linkage	Offspring of siblings	Registry-based information on RT (yes/no) Information on CT abstracted from medical records (for survivors with affected outcomes only)	Chromosomal abnormalities (eight survivors with one or more children) fetuses with an abnormal karyotype)	Proportion of live-born children with abnormal karyotypes born to CS was 0.21% and for siblings, 0.21% Direct comparison with siblings' offspring: Down syndrome (RR, 1.07; 95% CI, 0.16 to 5.47), Turner syndrome (RR, 1.32; 95% CI, 0.17 to 7.96) Male:female ratio CCS offspring v general population: 1.08 (range, 1.01-1.15) v 1.05 RT only v no RT and CT (OR, 0.97; 95% CI, 0.81 to 1.16) CT only v no RT and CT (OR, 1.00; 95% CI, 0.77 to 1.30) High- v low-dose gonadal RT (OR, 0.95; 95% CI, 0.77 to 1.18)
Reulen <sup>64</sup>	BCCSS: National Registry of Childhood Tumors, diagnosis < 15 years of age (1940-1991)	6,232 born to 3,218 female and male CS	Questionnaire obtained from general practitioners	General population of England and Wales Internal comparisons among female CCS (CCS without CT/RT; high v low gonadal dose)	Registry-based information on RT (yes/no) and CT (yes/no) High v low estimated RT dose to gonads	Sex ratio alterations (6,232 offspring)	Male:female ratio CCS offspring v general population: 1.08 (range, 1.01-1.15) v 1.05 RT only v no RT and CT (OR, 0.97; 95% CI, 0.81 to 1.16) CT only v no RT and CT (OR, 1.00; 95% CI, 0.77 to 1.30) High- v low-dose gonadal RT (OR, 0.95; 95% CI, 0.77 to 1.18)
Magelssen <sup>46</sup>	CS: Norway, diagnosis 15-35 years of age (1980-1997)	First born (number not stated) to 251 female and 487 male CS	Registry information	First-born offspring in the general population of Norway	Hospital-based information on cancer treatment Four categories: surgery alone, RT ( $\pm$ surgery), CT ( $\pm$ surgery), and RT and CT ( $\pm$ surgery); not included in analyses for malformation outcome)	Congenital malformations (n = 7)	OR of 0.7 (95% CI 0.4 to 1.6) in female CS

(continued on following page)

Table 2. Health Risk Outcomes in Cancer Survivor Offspring (continued)

First Author	Study Cohort	No. of Offspring	Outcome Assessment	Comparison	Cancer (treatment)	Health Risk Outcomes Measures	Risk Estimate
Winther <sup>59</sup>	CCS; Danish Cancer Registry, diagnosis < 20 years of age (1950-1996)	1,715 born to 970 CS	Registry linkage	Offspring of siblings	Registry-based information on RT (yes/no) Four categories of estimated RT dose to ovary and uterus: low, low-medium, medium-high, and high	Congenital malformations (n = 44 at birth; n = 96 later in life)	PPR at birth, survivors' v siblings' offspring: 1.1 (95% CI, 0.8 to 1.5) v general Danish population (O/E, 1.2; 95% CI, 0.9 to 1.6) Offspring of irradiated v nonirradiated parents (PPR, 1.2 v 1.0 at birth), including malformations diagnosed later in life, no ratio change
Muelle <sup>45</sup>	CS; Seattle, WA; Utah; Detroit, MI; and Atlanta, GA, diagnosis < 20 years of age (1973-2000)	1,898 first live births born to 898 CS, 892 CCS, and 1,006 adolescent cervical and genital CS	Registry linkage	Comparison offspring selected from birth records	Registry-based information on cancer therapy Four categories: CT, surgery, RT, and combinations	Congenital malformations (n = 10) Sex ratio alterations (1,898 offspring)	RR, 0.92 (95% CI, 0.48 to 1.75) Male:female ratio among offspring in the two cohorts and comparisons similar (range, 0.98-1.02) CCS: RR, 1.00 (95% CI, 0.93 to 1.07) Adolescent cervical and genital CS: RR, 0.97 (95% CI, 0.90 to 1.03) No significant increased RRs for malformations across groups
Madanat-Harjuoja <sup>63</sup>	CS; Finnish Cancer Registry, diagnosis < 35 years of age (1953-2004)	26,331 born to 12,735 CS 9,877 born after parent diagnosis (4,764 female and 5,113 male CS)	Registry linkage	Population expectations on the basis of cancer incidence rates in Finland (SIR) Indirect comparison with offspring of siblings	Registry-based information on RT (yes/no)	Cancer (n = 65 in children born after their parent's diagnosis)	Offspring of CS: SIR, 1.67 (95% CI, 1.29 to 2.12) Offspring of CS, excluding hereditary cases: SIR, 1.03 (95% CI, 0.74 to 1.40) Offspring of siblings: SIR, 1.07 (95% CI, 0.94 to 1.21) RT no effect on the risk: SIR, 0.91 (95% CI, 0.51 to 1.49)
Green <sup>70</sup>	National Wilms Tumor LTFUS; female CCS (and partners of male CS of Wilms tumor; earlier than January 2007)	1,021 pregnancies of ≥ 20 weeks duration, including 955 live born singletons; 677 included in analyses of 2,369 female CS and partners of 2,060 male CS	Self-administered questionnaire	Internal comparison	RT doses estimated on the basis of RT treatment protocols and each patient assigned a flank irradiation dose category except for those who received whole-abdomen irradiation Five dose categories in Grays	Congenital malformations (n = 44)	P for trend with radiation dose = .94

(continued on following page)

**Table 2.** Health Risk Outcomes in Cancer Survivor Offspring (continued)

First Author	Study Cohort	No. of Offspring	Outcome Assessment	Comparison	Cancer (treatment)	Health Risk Outcomes Measures	Risk Estimate
Winther <sup>62</sup>	CCS: Danish Cancer Registry, diagnosis < 20 years of age (1950-1996)	1,920 born to 527 female and 539 male CS	Registry linkage	Offspring of siblings. Population-based comparisons	Registry-based information on RT (yes/no) Four categories of estimated RT dose to ovary, uterus and pituitary gland: low, low-medium, medium-high, and high	Untoward disorders measured as hospitalization in childhood with the assumption that hospitalization is an indicator of multifactorial genetic disease (1,053 discharge diagnoses in CS offspring)	HR ratios compared with population: CS's offspring: (HRR, 1.05; 95% CI, 0.98 to 1.12), siblings' offspring (HHR, 1.01; 95% CI, 0.97 to 1.05) HRR irradiated parents v nonirradiated parents on the basis of population comparisons (1.1 v 1.0) but unrelated to estimated radiation dose to gonads A sixfold excess risk for hospitalization for malignant tumors in the offspring of survivors largely explained by hereditary cancer syndromes
Winther <sup>66</sup>	CS; Danish Cancer Registry, diagnosis < 20 years of age (1943-1996)	472 CS; 145 case CS (with affected child or stillbirth) and 372 subcohort members (including 45 patients) (one third of a fertility cohort consisted of 1,474 CS with 2,767 pregnancies included in Winther <sup>62</sup> )	Registry linkage	Internal comparison: nonirradiated survivors (for association with RT overall and with ovarian and uterine and testicular dose) Nonexposed to CT (for association with CT overall)	Medical records, including detailed information on CT and individual preconception RT doses to ovaries, uterus, and pituitary gland	Genetic diseases defined as chromosomal abnormalities, congenital malformations, stillbirths, and neonatal deaths (181 presumed genetic diseases in offspring)	Dose-response findings: RRs for ovarian RT dose categories > 0 to < 0.50 Gy and ≥ 0.50 Gy (with nonirradiated being reference): 1.12 and 1.04, respectively (P = .96) Risk of genetic disease among children of CS: irradiated v nonirradiated CS: RR, 1.02 (95% CI, 0.59 to 1.44; P = .94) AA v no AA agents in CS: RR, 0.82 (95% CI, 0.53 to 1.28; P = .51) An association between uterine dose and congenital malformations, stillbirths, and neonatal death, taken together, was of borderline statistical significance (P = .07), with the highest uterine doses associated with a 2.3-fold increased risk (not significant).

(continued on following page)



Table 2. Health Risk Outcomes in Cancer Survivor Offspring (continued)

First Author	Study Cohort	No. of Offspring	Outcome Assessment	Comparison	Cancer (treatment)	Health Risk Outcomes Measures	Risk Estimate
Signorello <sup>55</sup>	CCSS: Canada/United States, diagnosis < 21 years of age (1970-1986)	4,699 born to 1,627 female and 1,128 male CS	Self-administered questionnaire	Internal comparison Nonirradiated CS (for association with RT dose) Nonexposed to CT (for association with CT)	Medical records, including AAD score: 1-3 (lowest, middle, and top tertile exposure) and individual preconception RT doses to the gonads	Congenital anomalies defined as cytogenetic abnormalities, single-gene defects, and congenital malformations (129 offspring with congenital anomalies)	Dose-response findings: ORs for ovarian RT dose categories low, medium, and high, 0.87, 0.80, and 0.59 respectively (P for trend with radiation dose = .53) ORs for AAD score categories lowest, middle, and top tertile exposure, 0.63, 1.00, and 1.13, respectively (P for trend with AAD score = .69) For congenital malformations, ORs for ovarian radiation dose categories ranged from 0.84 to 1.14, which suggested no adverse effect. AAD score analysis showed a nonsignificant decreased risk for the lowest and nonsignificant increased risks for the middle and top tertile exposure.
Haggart <sup>54</sup>	CS: Western Australia Cancer Registry, diagnosis 15-39 years of age (1982-2007)	1,894 first completed pregnancies of 1,894 female CS	Registry linkage	Population-based comparisons without cancer	Five treatment groups: surgery only, CT only, RT only, CT and RT, and all other types and therapy combinations (not included in analyses for malformation outcome)	Congenital malformations (n = 12) Sex ratio alterations (1,894 offspring)	RR, 0.78 (95% CI, 0.41 to 1.37) Male:female ratio: RR, 1.05 (95% CI, 0.98 to 1.10)
Seppanen <sup>60</sup>	CS: Finnish Cancer Registry, diagnosis < 35 years of age (1953-2004)	6,862 born to 3,929 CS (2,197 female and 1,732 male) 2,412 born to CCS 4,450 born to young adult CS	Registry linkage	Offspring of siblings	Registry-based information on RT (yes/no)	Congenital malformations (n = 220)	PRs for CS's v siblings' offspring: Any anomaly: 1.17 (95% CI, 0.92 to 1.49) Lip and palate anomalies: 2.09 (95% CI, 1.06 to 4.12) Any anomaly in offspring of retinoblastoma: 3.15 (95% CI, 1.37 to 7.23) Renal tumors: 2.13 (95% CI, 1.07 to 4.26; small number) No association with RT of the parent: 1.12 (95% CI, 0.86 to 1.45)

NOTE: The health risk outcome measures miscarriage, stillbirth, and perinatal death are evaluated in the Pregnancy Outcomes section. Abbreviations: AA, alkylating agents; AAD, alkylating agent dose; AP, abdominopelvic; BCCSS, British Childhood Cancer Survivor Study; CCS, childhood cancer survivors; CCSS, Childhood Cancer Survivor Study; CS, cancer survivors; CT, chemotherapy; HR, hospitalization rate; HRR, hospitalization rate ratio; LTFUS, long-term follow-up study; O/E, observed/expected; OR, odds ratio; PPR, prevalence proportion ratio; PR, prevalence ratio; RR, risk ratio; RT, radiotherapy; SiR, standardized incidence rate.

that may no longer be in practice and may be less applicable for counseling patients treated with more-contemporary treatment strategies.

## HEALTH RISKS IN OFFSPRING

Childhood cancer survivors represent one of the largest groups of people exposed to well-documented high doses of potent mutagens in the form of chemotherapy and radiation therapy that might affect human germ cells and cause potential transmissibility of germline damage to offspring.<sup>57</sup> Health indicators of a possible mutagenic effect of cancer therapy that have been considered include single-gene disorders and chromosomal abnormalities (rare but purely genetic diseases); the relatively common congenital malformations (which although to some extent genetically determined, are multifactorial); and miscarriage, stillbirths, and perinatal death. The occurrence of cancer and sex ratio alterations also have been considered as appropriate measures of germ cell mutations in the next generation. Although most early studies lacked sufficient statistical power, their findings have suggested a low risk of treatment-induced heritable genetic effects. Findings of more-recent, larger, and refined studies are listed in Table 2.

Five population-based Nordic studies on the risk of sex ratio,<sup>58</sup> congenital malformations,<sup>59,60</sup> chromosomal abnormalities,<sup>61</sup> and hospitalizations<sup>62</sup> in offspring of survivors did not observe a significantly increased risk. In the largest population-based study to date that evaluated cancer risk in the next generation, 9,877 children born to survivors showed no increased risk of cancer except in the rare event of a familial cancer syndrome.<sup>63</sup> A population-based cohort study from the British Childhood Cancer Survivor Study that reported on sex ratio alterations<sup>64</sup> maximized the statistical power by pooling its data with those from previous large-scale studies.<sup>58</sup> The sex ratio of the offspring of survivors treated with potentially high-dose gonadal irradiation was not significantly different from that of survivors treated with presumably low-dose gonadal irradiation (odds ratio, 0.92; 95% CI, 0.78 to 1.08). These findings were confirmed by more-recent studies in the United States<sup>45</sup> and Western Australia.<sup>54</sup>

Although the design and methodology differed among the more recently published studies on the risk of congenital malformations in offspring, no significantly increased risks have been reported.<sup>45,46,51,54,59,60</sup> Two comprehensive studies evaluated the risk of genetic disease in children of childhood cancer survivors.<sup>65,66</sup> and provided strong evidence that potentially mutagenic chemotherapy and radiotherapy doses to the ovaries are not associated with genetic defects in the children. Consistent with the epidemiologic studies, no evidence for an increased rate of germline minisatellite mutations at hypervariable loci, markers for radiation-induced human germline mutation, was identified in parents who had received radiotherapy.<sup>67</sup>

To date, no environmental exposure, including cancer therapy, has been proven to cause human germline mutations that manifest as heritable disease in offspring.<sup>57</sup> Inadequate study size has been suggested, and failure to measure the appropriate outcome might explain the reassuring results reported in the majority of studies on health risks in offspring.<sup>57</sup> Total genomic sequencing

that directly evaluates the presence of genetic damage in germ cells and epigenomic analysis might be ways to address this issue in the future, particularly in the era of targeted cancer therapies that include epigenetic modifiers.<sup>68</sup>

In conclusion, over the past decades, the adverse effects of cancer and its therapy on reproductive outcomes have become clear, especially after specific treatment, yet significant gaps in knowledge continue to limit the ability to assess risk for gonadal failure in individual patients who receive these therapies. Little is known about how host factors, such as genetic risks for infertility or differences in drug metabolism, affect risk from treatment. The effect of newer (molecular-targeted) agents is virtually unknown, and after therapy is delivered and a gonadotoxic insult has occurred, we know little about whether there is compensation in the rate of decline of ovarian reserve. Furthermore, the methods by which we assess impending ovarian insufficiency and loss of the reproductive window still remain inexact, which limits the ability to counsel survivors about making reproductive decisions.

We recommend that all clinical trials and treatment strategies for patients with cancer include surveillance for adverse effects on reproductive health, which in female patients should include assessment of ovarian function, pregnancy outcomes, and fertility (Fig 2). Detailed information about chemotherapy and radiotherapy exposures should be collected routinely to correlate with reproductive outcomes because treatment exposures rather than the nature of the cancer largely determine risks for chronic health conditions, including gonadal function and fertility in cancer survivors. Survivors should receive personalized counseling about type and magnitude of reproductive health risks on the basis of their specific treatment exposure, and studies should be established to determine the efficacy of fertility preservation procedures undertaken in this population.

Although oncofertility options have expanded globally, a need still exists to identify the specific fertility threats related to the primary cancer and treatment patterns by country. De Roo et al<sup>69</sup> proposed a global oncofertility index to permit experts to determine the scale of the problem and facilitate the development of educational tools that define access to reproductive technologies. As identified in the International Late Effects of Childhood Cancer Guideline Harmonization Group POI guideline, major gaps exist in information about safe treatment dosages, safety of novel therapies, and the role of genetic susceptibility on subsequent POI risk in survivors.<sup>19</sup>

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at [jco.org](http://jco.org).

## AUTHOR CONTRIBUTIONS

**Conception and design:** Wendy van Dorp, Riccardo Haupt, Melissa M. Hudson, Jennifer M. Levine, W. Hamish Wallace

**Collection and assembly of data:** Wendy van Dorp, Richard A. Anderson, Renee L. Mulder, Marry M. van den Heuvel-Eibrink, Eline van

Dulmen-den Broeder, H. Irene Su, Jeanette F. Winther, Jennifer M. Levine, W. Hamish Wallace

**Data analysis and interpretation:** All authors

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

REFERENCES

1. Geenen MM, Cardous-Ubbink MC, Kremer LC, et al: Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. *JAMA* 297:2705-2715, 2007
2. Oeffinger KC, Mertens AC, Sklar CA, et al: Chronic health conditions in adult survivors of childhood cancer. *N Engl J Med* 355:1572-1582, 2006
3. Gilleland Marchak J, Elchuri SV, Vangile K, et al: Perceptions of infertility risks among female pediatric cancer survivors following gonadotoxic therapy. *J Pediatr Hematol Oncol* 37:368-372, 2015
4. Anderson RA, Mitchell RT, Kelsey TW, et al: Cancer treatment and gonadal function: Experimental and established strategies for fertility preservation in children and young adults. *Lancet Diabetes Endocrinol* 3:556-567, 2015
5. Webber L, Davies M, Anderson R, et al: ESHRE guideline: Management of women with premature ovarian insufficiency. *Hum Reprod* 31:926-937, 2016
6. Sklar CA, Mertens AC, Mitby P, et al: Premature menopause in survivors of childhood cancer: A report from the childhood cancer survivor study. *J Natl Cancer Inst* 98:890-896, 2006
7. Chemaitilly W, Li Z, Krasin MJ, et al: Premature ovarian insufficiency in childhood cancer survivors: A report from the St. Jude Lifetime Cohort. *J Clin Endocrinol Metab* 102:2242-2250, 2017
8. Levine JM, Whitton JA, Ginsberg JP, et al: Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. *Cancer* 124:1044-1052, 2018
9. Findlay JK, Hutt KJ, Hickey M, et al: How is the number of primordial follicles in the ovarian reserve established? *Biol Reprod* 93:111, 2015
10. Wallace WHB, Anderson RA, Irvine DS: Fertility preservation for young patients with cancer: Who is at risk and what can be offered? *Lancet Oncol* 6:209-218, 2005
11. Overbeek A, van den Berg MH, van Leeuwen FE, et al: Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. *Cancer Treat Rev* 53:10-24, 2017
12. Wallace WH, Thomson AB, Saran F, et al: Predicting age of ovarian failure after radiation to a field that includes the ovaries. *Int J Radiat Oncol Biol Phys* 62:738-744, 2005
13. Imai A, Ichigo S, Matsunami K, et al: Ovarian function following targeted anti-angiogenic therapy with bevacizumab. *Mol Clin Oncol* 6:807-810, 2017
14. Zamah AM, Mauro MJ, Druker BJ, et al: Will imatinib compromise reproductive capacity? *Oncologist* 16:1422-1427, 2011
15. Morgan S, Lopes F, Gourley C, et al: Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. *PLoS One* 8:e70117, 2013
16. Clement SC, Kraal KC, van Eck-Smit BL, et al: Primary ovarian insufficiency in children after treatment with <sup>131</sup>I-metaiodobenzylguanidine for neuroblastoma: Report of the first two cases. *J Clin Endocrinol Metab* 99:E112-E116, 2014
17. De Vos M, Devroey P, Fauser BC: Primary ovarian insufficiency. *Lancet* 376:911-921, 2010
18. Kremer LC, Mulder RL, Oeffinger KC, et al: A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Pediatr Blood Cancer* 60:543-549, 2013
19. van Dorp W, Mulder RL, Kremer LC, et al: Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. *J Clin Oncol* 34:3440-3450, 2016
20. Dutch Childhood Oncology Group: Richtlijn follow-up na kinderkanker meer dan 5 jaar na diagnose, 2010. <https://www.skion.nl/voor-patienten-en-ouders/late-effecten/533/richtlijn-follow-up-na-kinderkanker>
21. Scottish Intercollegiate Guidelines Network: Long term follow up of survivors of childhood cancer. A national clinical guideline. Edinburgh, UK, 2013
22. United Kingdom Children's Cancer Study Group Late Effects Group: Therapy Based Long Term Follow Up Practice Statement (ed 2), 2005. <https://www.uhb.nhs.uk/Downloads/pdf/CancerPbTherapyBasedLongTermFollowUp.pdf>
23. Children's Oncology Group: Long-term follow-up guidelines for survivors of childhood adolescent, and young adult cancers, version 4.0, 2018. <http://www.survivorshipguidelines.org>
24. Dunlop CE, Anderson RA: Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women. *Maturitas* 80:245-250, 2015
25. Rees MC: Hormone replacement therapy is indeed indicated. *BMJ* 336:1148, 2008
26. O'Donnell RL, Warner P, Lee RJ, et al: Physiological sex steroid replacement in premature ovarian failure: Randomized crossover trial of effect on uterine volume, endometrial thickness and blood flow, compared with a standard regimen. *Hum Reprod* 27:1130-1138, 2012
27. Crofton PM, Evans N, Bath LE, et al: Physiological versus standard sex steroid replacement in young women with premature ovarian failure: Effects on bone mass acquisition and turnover. *Clin Endocrinol (Oxf)* 73:707-714, 2010
28. Langrish JP, Mills NL, Bath LE, et al: Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. *Hypertension* 53:805-811, 2009
29. Moskowitz CS, Chou JF, Sklar CA, et al: Radiation-associated breast cancer and gonadal hormone exposure: A report from the Childhood Cancer Survivor Study. *Br J Cancer* 117:290-299, 2017
30. Green DM, Kawashima T, Stovall M, et al: Fertility of female survivors of childhood cancer: A report from the childhood cancer survivor study. *J Clin Oncol* 27:2677-2685, 2009
31. Stensheim H, Cvancarova M, Møller B, et al: Pregnancy after adolescent and adult cancer: A population-based matched cohort study. *Int J Cancer* 129:1225-1236, 2011
32. Chow EJ, Stratton KL, Leisenring WM, et al: Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: A report from the Childhood Cancer Survivor Study cohort. *Lancet Oncol* 17:567-576, 2016
33. Reulen RC, Zeegers MP, Wallace WH, et al: Pregnancy outcomes among adult survivors of childhood cancer in the British Childhood Cancer Survivor Study. *Cancer Epidemiol Biomarkers Prev* 18:2239-2247, 2009
34. Pivetta E, Maule MM, Pisani P, et al: Marriage and parenthood among childhood cancer survivors: A report from the Italian AIEOP Off-Therapy Registry. *Haematologica* 96:744-751, 2011
35. Armuand G, Skoog-Svanberg A, Bladh M, et al: Reproductive patterns among childhood and adolescent cancer survivors in Sweden: A population-based matched-cohort study. *J Clin Oncol* 35:1577-1583, 2017
36. Barton SE, Najita JS, Ginsburg ES, et al: Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: A report from the Childhood Cancer Survivor Study cohort. *Lancet Oncol* 14:873-881, 2013
37. Brämstig JH, Riepenhausen M, Schellong G: Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: A prospective, longitudinal study. *Lancet Oncol* 16:667-675, 2015
38. Winther JF, Boice JD Jr, Svendsen AL, et al: Spontaneous abortion in a Danish population-based cohort of childhood cancer survivors. *J Clin Oncol* 26:4340-4346, 2008
39. Green DM, Whitton JA, Stovall M, et al: Pregnancy outcome of female survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. *Am J Obstet Gynecol* 187:1070-1080, 2002
40. Zynka A, Reinmuth S, Pfitzer C, et al: Childhood leukemia and its impact on graduation and having children: Results from a national survey. *Leuk Lymphoma* 53:2419-2422, 2012
41. Arrivé L, Chang YC, Hricak H, et al: Radiation-induced uterine changes: MR imaging. *Radiology* 170:55-58, 1989
42. Critchley HO, Wallace WH, Shalet SM, et al: Abdominal irradiation in childhood; the potential for pregnancy. *Br J Obstet Gynaecol* 99:392-394, 1992
43. Critchley HO, Wallace WH: Impact of cancer treatment on uterine function. *J Natl Cancer Inst Monogr* 2005:64-68, 2005
44. Signorello LB, Cohen SS, Bosetti C, et al: Female survivors of childhood cancer: Preterm birth and low birth weight among their children. *J Natl Cancer Inst* 98:1453-1461, 2006
45. Mueller BA, Chow EJ, Kaminen A, et al: Pregnancy outcomes in female childhood and adolescent cancer survivors: A linked cancer-birth registry analysis. *Arch Pediatr Adolesc Med* 163:879-886, 2009
46. Magelssen H, Melve KK, Skjaerven R, et al: Parenthood probability and pregnancy outcome in patients with a cancer diagnosis during adolescence and young adulthood. *Hum Reprod* 23:178-186, 2008
47. Fosså SD, Magelssen H, Melve K, et al: Parenthood in survivors after adulthood cancer and perinatal health in their offspring: A preliminary report. *J Natl Cancer Inst Monogr* 2005:77-82, 2005
48. Green DM, Sklar CA, Boice JD Jr, et al: Ovarian failure and reproductive outcomes after childhood cancer treatment: Results from the Childhood Cancer Survivor Study. *J Clin Oncol* 27:2374-2381, 2009

49. Green DM, Peabody EM, Nan B, et al: Pregnancy outcome after treatment for Wilms tumor: A report from the National Wilms Tumor Study Group. *J Clin Oncol* 20:2506-2513, 2002
50. Li FP, Gimbere K, Gelber RD, et al: Outcome of pregnancy in survivors of Wilms' tumor. *JAMA* 257:216-219, 1987
51. Chiarelli AM, Marrett LD, Darlington GA: Pregnancy outcomes in females after treatment for childhood cancer. *Epidemiology* 11:161-166, 2000
52. Signorello LB, Mulvihill JJ, Green DM, et al: Stillbirth and neonatal death in relation to radiation exposure before conception: A retrospective cohort study. *Lancet* 376:624-630, 2010
53. Lie Fong S, van den Heuvel-Eibrink MM, Eijkemans MJ, et al: Pregnancy outcome in female childhood cancer survivors. *Hum Reprod* 25:1206-1212, 2010
54. Haggard FA, Pereira G, Preen D, et al: Adverse obstetric and perinatal outcomes following treatment of adolescent and young adult cancer: A population-based cohort study. *PLoS One* 9:e113292, 2014
55. Hines MR, Mulrooney DA, Hudson MM, et al: Pregnancy-associated cardiomyopathy in survivors of childhood cancer. *J Cancer Surviv* 10:113-121, 2016
56. Armenian SH, Hudson MM, Mulder RL, et al: Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol* 16:e123-e136, 2015
57. Boice JD Jr, Tawn EJ, Winther JF, et al: Genetic effects of radiotherapy for childhood cancer. *Health Phys* 85:65-80, 2003
58. Winther JF, Boice JD Jr, Thomsen BL, et al: Sex ratio among offspring of childhood cancer survivors treated with radiotherapy. *Br J Cancer* 88:382-387, 2003
59. Winther JF, Boice JD Jr, Frederiksen K, et al: Radiotherapy for childhood cancer and risk for congenital malformations in offspring: A population-based cohort study. *Clin Genet* 75:50-56, 2009
60. Seppänen VI, Artama MS, Malila NK, et al: Risk for congenital anomalies in offspring of childhood, adolescent and young adult cancer survivors. *Int J Cancer* 139:1721-1730, 2016
61. Winther JF, Boice JD Jr, Mulvihill JJ, et al: Chromosomal abnormalities among offspring of childhood-cancer survivors in Denmark: A population-based study. *Am J Hum Genet* 74:1282-1285, 2004
62. Winther JF, Boice JD Jr, Christensen J, et al: Hospitalizations among children of survivors of childhood and adolescent cancer: A population-based cohort study. *Int J Cancer* 127:2879-2887, 2010
63. Madanat-Harjuoja LM, Malila N, Lähteenmäki P, et al: Risk of cancer among children of cancer patients - A nationwide study in Finland. *Int J Cancer* 126:1196-1205, 2010
64. Reulen RC, Zeegers MP, Lancashire ER, et al: Offspring sex ratio and gonadal irradiation in the British Childhood Cancer Survivor Study. *Br J Cancer* 96:1439-1441, 2007
65. Signorello LB, Mulvihill JJ, Green DM, et al: Congenital anomalies in the children of cancer survivors: A report from the Childhood Cancer Survivor Study. *J Clin Oncol* 30:239-245, 2012
66. Winther JF, Olsen JH, Wu H, et al: Genetic disease in the children of Danish survivors of childhood and adolescent cancer. *J Clin Oncol* 30:27-33, 2012
67. Tawn EJ, Rees GS, Leith C, et al: Germline minisatellite mutations in survivors of childhood and young adult cancer treated with radiation. *Int J Radiat Biol* 87:330-340, 2011
68. Mulvihill JJ: Preconception exposure to mutagens: Medical and other exposures to radiation and chemicals. *J Community Genet* 3:205-211, 2012
69. de Roo SF, Rashedi AS, Beerendonk CCM, et al: Global oncofertility index-data gap slows progress. *Biol Reprod* 96:1124-1128, 2017
70. Green DM, Lange JM, Peabody EM, et al: Pregnancy outcome after treatment for Wilms tumor: A report from the national Wilms tumor long-term follow-up study. *J Clin Oncol* 28:2824-2830, 2010

### Affiliations

Wendy van Dorp, Erasmus University Medical Center, Rotterdam; Renee L. Mulder, Emma Children's Hospital and Academic Medical Center; Eline van Dulmen-den Broeder, VU University Medical Center, Amsterdam; Marry M. van den Heuvel-Eibrink, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Riccardo Haupt, Istituto Giannina Gaslini, Genoa, Italy; Richard A. Anderson and W. Hamish Wallace, University of Edinburgh; W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom; H. Irene Su, University of California, San Diego, CA; Jeanette F. Winther, Danish Cancer Society Research Center, Copenhagen, and Aarhus University, Aarhus, Denmark; Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; and Jennifer M. Levine, Weill Cornell Medicine, New York, NY.



**AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

**Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Review**

*The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/site/ifc](http://ascopubs.org/jco/site/ifc).*

**Wendy van Dorp**

No relationship to disclose

**Riccardo Haupt**

**Consulting or Advisory Role:** Novo Nordisk

**Richard A. Anderson**

**Honoraria:** IBSA Institut Biochimique SA

**Consulting or Advisory Role:** Roche, HRA Pharma, NeRRe Therapeutics

**Research Funding:** Ferring Pharmaceuticals

**Renee L. Mulder**

No relationship to disclose

**Marry M. van den Heuvel-Eibrink**

No relationship to disclose

**Eline van Dulmen-den Broeder**

No relationship to disclose

**H. Irene Su**

No relationship to disclose

**Jeanette F. Winther**

No relationship to disclose

**Melissa M. Hudson**

**Consulting or Advisory Role:** Coleman Supportive Oncology Initiative for Children with Cancer, Oncology Research Information Exchange Network, Pfizer, Princess Máxima Center

**Jennifer M. Levine**

No relationship to disclose

**W. Hamish Wallace**

No relationship to disclose